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Myo®broblasts are ®broblasts that express certain
features of smooth muscle differentiation. Increased
numbers of myo®broblasts and mast cells are fre-
quently found together in a wide variety of settings,
such as normal wound repair and scleroderma skin,
which suggests that mediators produced by the mast
cells could play a role in the regulation of myo®bro-
blast differentiation and function. We used a human
mast cell line, HMC-1, to determine if mast cells can
induce normal human dermal ®broblasts to differen-
tiate into functional myo®broblasts in vitro. We
monitored the differentiation process by assaying
two properties of the myo®broblast phenotype:
expression of a-smooth muscle actin and functional
capacity to contract a collagen matrix. In both a
simple coculture system and in a skin-equivalent
culture system, HMC-1 cells induced a-smooth
muscle actin expression by ®broblasts. HMC-1 cells
also stimulated ®broblast contraction of collagen
gels, and the relative amount of contraction was
dependent upon the number of HMC-1 cells present.
To characterize the individual contributions made
by speci®c mast cell products, we examined the
effects of histamine, tumor necrosis factor a, and
tryptase. Histamine induced a clear increase in a-
smooth muscle actin expression, but it did not
appear to stimulate ®broblast contraction. Tumor
necrosis factor a had no effect in either assay.
Puri®ed human tryptase induced a-smooth muscle
actin expression, and blocking the proteolytic activ-
ity of tryptase with speci®c inhibitors reduced that
response. Tryptase inhibitors also eliminated the
ability of HMC-1 cells to stimulate ®broblast con-
traction, suggesting that tryptase secreted by the
HMC-1 cells may be one of the active mast cell
mediators. Key words: a-actin/collagen/histamine/trans-
forming growth factor b/tryptase. J Invest Dermatol
117:1113±1119, 2001
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lthough ®broblasts are abundant in connective tissues
throughout the body, not all populations of
®broblasts are homogeneous (Sappino et al, 1990b;
Schmitt-GraÈff et al, 1994). Some ®broblasts express
features of smooth muscle differentiation. These
smooth muscle-like ®broblasts are referred to as myo®broblasts
(Serini and Gabbiani, 1999) and they can be identi®ed by certain
characteristic features of the cytoskeleton, particularly by the
expression of a-smooth muscle actin (Sappino et al, 1990b).
Myo®broblasts make important contributions to the growth and
differentiation of tissues and organs through their interactions with
epithelial cells (Gabbiani et al, 1971; Gabbiani and Majno, 1972;
Schmitt-GraÈff et al, 1994; Gabbiani, 1998; Powell et al, 1999; Serini
and Gabbiani, 1999). They play a major role in in¯ammatory
responses and in wound repair through their production of growth
factors, cytokines, and other soluble mediators. Myo®broblasts also
contribute to wound repair by contracting granulation tissue to
reduce wound volume, and by repairing damaged extracellular
matrix through the synthesis of collagen, ®bronectin, and
proteoglycans. When myo®broblast activity is not regulated
properly, however, the result may be destructive tissue remodeling
(Adler et al, 1989; Hebda et al, 1993; Weber, 1997; Powell et al,
1999). Myo®broblasts appear to play a fundamental role in many
diseases, including scleroderma (Sappino et al, 1990a; Kirk et al,
1995), hepatic and pancreatic ®brosis (Bachem et al, 1998;
Friedman, 2000), and pulmonary ®brosis (Gauldie et al, 1999;
Low, 1999).
Perhaps the most critical event in the normal process of wound
repair and in the evolution of ®brosis is the appearance of activated
myo®broblasts (Powell et al, 1999). These cells can apparently
originate from several different sources, and a number of different
activating factors may be involved. Mast cells are a potential source
of some of those factors. One remarkably consistent ®nding is that
myo®broblasts arise in a wide variety of settings concurrently with a
local increase in the number of tissue mast cells (Choi and Claman,
1987; Rothe and Kerdel, 1991; Hebda et al, 1993). The concept
that biologically signi®cant interactions occur between mast cells
and ®broblasts is supported by the fact that numerous mediators
produced by mast cells, such as histamine, tumor necrosis factor a
(TNF-a), and tryptase, can in¯uence ®broblast development,
proliferation, and behavior. Tryptase, for example, is a serine
protease unique to mast cells, and it can stimulate ®broblast
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proliferation (Ruoss et al, 1991; Hartmann et al, 1992; Abe et al,
1998) and collagen synthesis (Cairns and Walls, 1997; Gruber et al,
1997; Abe et al, 1998). As mast cells have such pleiotropic effects on
®broblasts, we explored the possibility that speci®c mast cell
products might be able to induce normal human dermal ®broblasts
to differentiate into functional myo®broblasts.
MATERIALS AND METHODS
Cell culture Several different ®broblast cultures were used over the
course of this work. One culture of normal human ®broblasts isolated
from foreskin, AG01523C, was obtained from the National Institute on
Aging, Aging Cell Culture Repository, Coriell Institute for Medical
Research (Camden, NJ). These cells were fed minimum essential
medium containing Earle's salts, and 26 mM sodium bicarbonate,
25 mM HEPES, pH 7.3 (catalog #42360, Life Technologies,
Gaithersburg, MD), supplemented with nonessential amino acids
(#11140, Life Technologies), 10% fetal bovine serum (HyClone
Laboratories, Logan, UT), 100 U per ml penicillin and 100 mg per ml
streptomycin. Three other cultures of foreskin ®broblasts were prepared
in this laboratory from enzyme-digested tissue. These cultures were fed
Dulbecco's modi®ed Eagle's medium (DMEM; #12100, Life
Technologies), supplemented with 44 mM sodium bicarbonate, 1 mM
sodium pyruvate, 10% heat-inactivated fetal bovine serum, 100 U per ml
penicillin, 100 mg per ml streptomycin, and 250 ng per ml fungizone
(Life Technologies). All ®broblast cultures were maintained in an
atmosphere of 5% CO2 at 37°C.
The human mast cell line, HMC-1 (Butter®eld et al, 1988), was
obtained from J. H. Butter®eld (Mayo Clinic, Rochester, MN). Cultures
of HMC-1 cells were grown at 37°C, 5% CO2, in Iscove's modi®ed
Dulbecco's medium (IMDM; catalog #12200, Life Technologies),
supplemented with 36 mM sodium bicarbonate, 1.2 mM monothiogly-
cerol (Sigma-Aldrich, St. Louis, MO), 10% heat-inactivated fetal bovine
serum, 100 U per ml penicillin, 100 mg per ml streptomycin, and 250 ng
per ml fungizone.
A freeze/thaw lysate of HMC-1 cells was prepared by the following
procedure. HMC-1 cells were washed once with IMDM supplemented
only with 36 mM sodium bicarbonate, resuspended in the same medium
at a concentration of 5 3 106 cells per ml, and then sequentially frozen
and thawed ®ve times. Finally, the cell lysate was clari®ed by centrifuga-
tion to remove cell debris. The concentration of total protein in a typical
lysate preparation was »0.5 mg per ml, as measured in the BCA protein
assay (Pierce, Rockford, IL).
Organotypic skin cultures were prepared as described previously
(Garlick and Taichman, 1994b; Gruber et al, 1997). The culture system
used here consisted of a collagen gel matrix, containing human foreskin
®broblasts and human dermal microvascular endothelial cells, supporting
a strati®ed layer of human foreskin keratinocytes. In some cases, HMC-1
cells were also embedded in the collagen gel. Organotypic cultures, or
rafts, were grown submerged for 5 d and then raised to the air interface
for another 5 d to allow for complete strati®cation and differentiation of
surface keratinocytes. We have used this skin-equivalent culture system
previously to study interactions between mast cells and dermal ®broblasts
(Meng et al, 1995; Gruber et al, 1997) because it manifests epithelial
strati®cation and other properties of living skin (Garlick and Taichman,
1994a, b).
Transforming growth factor b1 (TGF-b1) puri®ed from human
platelets, recombinant human platelet-derived growth factor BB (PDGF-
BB), and recombinant human TNF-a were purchased from R&D
Systems. Histamine (#H-7375) was purchased from Sigma-Aldrich.
Immunohistochemistry Normal human foreskin ®broblasts (105
cells) were grown for 24 h on glass coverslips (18 mm 3 18 mm) in
complete medium containing serum, and then HMC-1 cells (106 cells)
or TGF-b1 (5 ng per ml) was added to some of the coverslips and
cultures were continued for an additional 48 h. The coverslips were
washed once gently with phosphate-buffered saline (PBS) before the cells
were ®xed with ice-cold acetone for 15 min. The ®xed cells were
washed three times with PBS containing 0.05% Tween 20 (PBS/T) and
then stained with a mouse monoclonal antibody speci®c for a-smooth
muscle actin, clone 1A4 from Sigma-Aldrich, followed by ¯uorescein
isthiocyanate conjugated goat antimouse IgG. To identify and locate
mast cells, coverslips to which HMC-1 cells had been added were
stained a second time using a monoclonal antibody against human
tryptase (clone B2 from L.B. Schwartz, Virginia Commonwealth
University, Richmond, VA) followed by a TRITC conjugate.
Organotypic cultures containing ®broblasts and HMC-1 cells, or
®broblasts without HMC-1 cells, were prepared and grown in complete
medium as described above. Paraf®n-embedded sections from individual
rafts were deparaf®nized, rehydrated with PBS, ®xed in acetone, blocked
for 60 min with 1% nonfat milk in PBS, and then incubated with the
1A4 anti-a smooth muscle actin monoclonal antibody for 60 min at
room temperature. After sections were washed three times with PBS,
they were incubated with biotinylated horse antimouse IgG for 30 min.
The slides were again washed before incubation with streptavidin±
alkaline phosphatase conjugate for 30 min. After three more washes, the
slides were developed with fast red substrate (BioGenex, San Ramon,
CA), and then counterstained with hematoxylin. To quantitate the results
of the staining, we counted the number of positive cells within a de®ned
area (450 mm 3 150 mm) on three different sections from each raft.
Collagen contraction assay This assay was adapted from a published
protocol (Greiling and Clark, 1997). Fibroblast cultures at 80%
con¯uence were harvested by treatment with 0.05% trypsin/0.02%
ethylenediamine tetraacetic acid (Clonetics, Walkersville, MD). Trypsin
was inactivated with trypsin neutralizing solution (Clonetics). The cells
were resuspended in DMEM containing 2% bovine serum albumin
(BSA) (DMEM/BSA) at a concentration of 1 3 106 cells per ml. The
®broblast suspension was mixed with neutralized collagen (Vitrogen 100,
Celtrix Laboratories, Santa Clara, CA), 5 3 concentrated DMEM, and
sodium bicarbonate, and, in certain experiments, HMC-1 cells. The ®nal
volume was adjusted so that DMEM and sodium bicarbonate were
present at normal strength and the concentration of collagen was 1.8 mg
per ml. The number of ®broblasts in the ®nal mixture was kept constant
at 500,000 ®broblasts per ml. In certain experiments, the mixture also
contained from 20,000 to 500,000 HMC-1 cells per ml. Aliquots
(0.5 ml) of the cell mixture were added to wells of a 24-well tissue
culture plate, which had been coated with 2% BSA, and the collagen
was allowed to polymerize at 37°C. After a 2 h incubation, the round
gels were gently detached from the plastic surface to allow contraction,
0.5 ml DMEM/BSA was added to each well, and the gels were
incubated at 37°C for 1±72 h. The DMEM/BSA fed to the cells at this
point, when speci®ed, contained fetal bovine serum (10%), PDGF-BB
(5 ng per ml), TGF-b1 (5 ng per ml), histamine (0.5±5 mg per ml), or
TNF-a (10±100 ng per ml). It is important to emphasize that the
DMEM/BSA medium used for the preparation and incubation of
collagen gels did not routinely contain serum; serum was present, to
stimulate contraction, only when speci®ed. The amount of contraction
was assessed by measuring collagen gel diameter after incubation for the
indicated time, usually 72 h. The results presented here are expressed as a
percentage of the contraction stimulated by PDGF-BB, which was used
at the optimal dose established in preliminary experiments. Stimulation
with PDGF-BB for 72 h typically caused the ®broblasts to contract the
collagen gels to 50% or less of the size of control, unstimulated gels.
Collagen gel contraction in all of these experiments was completely
dependent upon the presence of ®broblasts. Gels prepared without cells,
or with only HMC-1 cells, did not contract (data not shown).
Tryptase inhibitors were tested by adding the inhibitors to the
HMC-1 cell suspension (500,000 cells per ml) before the HMC-1 cells
were mixed with the ®broblasts and collagen solution as described above.
Bis(5-amidino-2-benzimidazolyl)methane (BABIM) was kindly provided
by R. Tidwell (University of North Carolina, Chapel Hill, NC).
Recombinant leech-derived tryptase inhibitor (rLDTI) was a generous
gift from C. P. Sommerhof (Abteilung fuÈr Klinische Chemie und
Klinische Biochemie in der Chirurgischen Klinik und Poliklinik,
MuÈnchen, Germany). BABIM (Caughey et al, 1993) and rLDTI
(Sommerhoff et al, 1994) are both speci®c inhibitors of tryptase
proteolytic activity. The general protocol described above was modi®ed
slightly to measure the effect of HMC-1 cells on ®broblast contraction
when the HMC-1 cells were cocultured with the ®broblast, but were
not incorporated into the collagen gel. In those experiments, the porous
membrane of a cell culture insert (catalog #3401, Corning Costar,
Cambridge, MA) was used to separate the HMC-1 cells from the
collagen gel, which contained only ®broblasts. The cup-shaped inserts
were carefully positioned a few millimeters above the collagen gels, and
0.5 ml aliquots of the HMC-1 cell suspension (500,000 cells per ml)
were dispensed directly into the inserts. Subsequent steps followed the
standard protocol.
Gel electrophoresis and immunoblotting Normal human dermal
®broblasts were seeded into six-well plates, 100,000 cells per well, and
fed culture medium fully supplemented with serum and the other
components listed above. After 24 h, cells were washed twice with PBS
and fed serum-free medium containing 2 mg per ml BSA (SFA). After
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another 24 h, cells were washed twice with PBS, and then either treated
as described below or fed SFA containing the speci®ed additions and
incubated for 72 h. Finally, the wells were washed three times with PBS
and the cells in each well were lysed with 0.1 ml of Tris-buffered saline
containing 1% sodium dodecyl sulfate (SDS) and protease inhibitors. The
protein concentration in each sample was determined with the BCA
protein assay using the supplied BSA as a standard. Equal amounts of
protein from each sample, typically 1±10 mg, were separated under
reducing conditions on a 10% Tris-HCl Ready Gel (Bio-Rad
Laboratories, Hercules, CA) in SDS running buffer, and then the
proteins were electrophoretically transferred to Immobilon-P membrane
(Millipore, Bedford, MA). The membrane blot was blocked with 1%
nonfat milk in PBS/T and then incubated with the 1A4 anti-a smooth
muscle actin monoclonal antibody, followed sequentially by biotinylated
antimouse IgG (Vector Laboratories, Burlingame, CA) and alkaline
phosphatase±streptavidin conjugate (Vector). After these incubations, the
immunoblot was stained using BCIP/NBT substrate (Kirkegaard & Perry
Laboratories, Gaithersburg, MD) and the stained immunoblot was
quantitated using NIH Image.
In certain experiments, ®broblast cultures were treated with tryptase
immediately before the 72 h incubation in SFA medium. Tryptase
solutions of 1±10 nM were prepared in SFA adjusted to pH 6.5 (Ren et
al, 1997, 1998). Aliquots of these solutions were incubated at ambient
temperature for 60 min with no additions, with 4-(2-aminoethyl)-
benzenesulfonyl ¯uoride hydrochloride (AEBSF Pefabloc SC; 2 mM), or
with a combination of soybean trypsin inhibitor (10 mg per ml) and
aprotinin (2 mg per ml). These three different tryptase solutions were
then applied to ®broblast cultures prepared as described above. The
cultures were incubated for 30 min at 37°C, washed twice with PBS,
and ®nally fed SFA containing the speci®ed additions and incubated for
72 h.
Puri®ed human lung tryptase, soybean trypsin inhibitor (#T-9003),
and aprotinin (#A-4529) were obtained from Sigma-Aldrich. AEBSF
was purchased from Roche Molecular Biochemicals (Indianapolis, IN).
RESULTS
The goal of this research was to determine if HMC-1 mast cells can
induce normal human dermal ®broblasts to differentiate into
functional myo®broblasts. We monitored the differentiation pro-
cess by assaying two important properties of the myo®broblast
phenotype: a-smooth muscle actin expression and functional
capacity to contract a collagen matrix. TGF-b1 was used as a
positive control in many of these experiments because it potently
induces a-smooth muscle actin expression (DesmoulieÁre et al,
1993; Ronnov-Jessen and Peterson, 1993) and markedly stimulates
collagen gel contraction (Montesano and Orci, 1988; Finesmith
et al, 1990; Fukamizu and Grinnell, 1990).
Fibroblast a-smooth muscle actin expression In the ®rst
set of experiments normal human dermal ®broblasts were cultured
on coverslips, either with or without HMC-1 cells, to determine if
the presence of mast cells could induce ®broblasts to express
a-smooth muscle actin. As shown in Fig 1, only a low level of
a-smooth muscle actin was detected in unstimulated ®broblasts
(Fig 1A). The immuno¯uorescence is weak and comparatively
diffuse. As expected, however, treating the ®broblasts with TGF-
b1 strongly induced a-smooth muscle actin expression (Fig 1C).
The cytoskeleton in the spindle-shaped ®broblasts is much more
brightly stained and many individual actin ®laments are discernible.
Notably, ®broblasts cocultured with HMC-1 cells were also
strongly induced to express a-smooth muscle actin (Fig 1B).
The effect of HMC-1 cells on a-smooth muscle actin expression
by ®broblasts was also studied using an organotypic (Garlick and
Taichman, 1994b), or skin-equivalent, culture system. Using this
culture system for an earlier study (Gruber et al, 1997), we
demonstrated that ®broblast synthesis of type a1(I) procollagen
mRNA was substantially increased in the presence of mast cells. To
determine if mast cells can also induce a-smooth muscle actin
expression by ®broblasts, HMC-1 cells and normal dermal
®broblasts were cultured together in the collagen layer of the
skin equivalent, and then a-smooth muscle actin expression in the
®broblasts was examined by immunostaining. Figure 2 demon-
strates that the presence of HMC-1 cells in the skin-equivalent
culture system greatly increased the number of ®broblasts positive
for a-smooth muscle actin. The average number of positive
®broblasts was 0.52 per mm2 for cultures containing HMC-1 cells,
but only 0.28 per mm2 for control cultures, where the staining of
individual cells was also less intense.
Fibroblast collagen contraction We next sought to
determine if increased a-smooth muscle actin expression in these
dermal ®broblasts was accompanied by an enhanced ability to
contract a collagen matrix, an important functional property of
Figure 1. HMC-1 cells induce a-smooth muscle actin expression
in dermal ®broblasts in vitro. Normal human dermal ®broblasts (105
cells) were grown on glass coverslips in complete medium. After 24 h,
HMC-1 cells (106 cells) or TGF-b1 (5 ng per ml) were added, and the
cells were cultured for an additional 48 h. The cultures were then
examined by immuno¯uorescence. (A) Control, untreated ®broblasts
stained for a-smooth muscle actin. (B) Fibroblasts cocultured with
HMC-1 cells stained for a-smooth muscle actin (green ¯uorescence),
and for tryptase (red ¯uorescence), to identify the HMC-1 cells. Areas
where the green and red ¯uorescence overlap appear yellow. (C)
Fibroblasts treated with TGF-b1 as a positive control and stained for a-
smooth muscle actin. Scale bar: 40 mm.
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myo®broblasts (Grinnell, 1994). Figure 3(A) presents results from
experiments measuring the effects of different treatments upon the
ability of normal human dermal ®broblasts to contract a collagen
gel in vitro. Serum, PDGF-BB, and TGF-b1 all stimulated ®broblast
contraction of the collagen gels, although TGF-b1 was less potent.
These factors were added to the culture medium surrounding the
gel. HMC-1 cells stimulated substantial ®broblast contraction when
they were incorporated into the collagen gels (Fig 3A, B), but they
had no effect on contraction when they were suspended above the
gel on a porous membrane (data not shown). Interestingly, the
contraction responses to HMC-1 cells and TGF-b1 displayed
similar kinetics. Both stimulated appreciable contraction after 2±
4 h, and nearly complete contraction after 8±10 h (Fig 3C). There
appeared to be a correlation between the number of HMC-1 cells
in the collagen gel and their capacity to stimulate ®broblast
contraction (Fig 3B). Lowering the number of HMC-1 cells in the
collagen gel to 40% or 20% of the number of ®broblasts produced
correspondingly less contraction. When the number of HMC-1
cells was reduced to 4% of the number of ®broblasts present in the
gel, no contraction was noted. One normal cell type, human
microvascular endothelial cells, and two transformed cell lines,
COS and HepG2, were also tested to determine if other cell types
could substitute for HMC-1 mast cells. None of these cells was able
to stimulate contraction (data not shown).
Effects of HMC-1 cell lysate Immunoblots were used to
con®rm our observation that HMC-1 cells induce a-smooth
muscle actin expression in ®broblasts, and to explore further the
mechanism through which this induction occurs. Normal human
dermal ®broblasts were cultured alone, or with either TGF-b1 or a
lysate prepared from HMC-1 cells (described in Materials and
Methods), and then the amount of a-smooth muscle actin expressed
under each condition was measured by immunoblotting.
Densitometry of the immunoblot shown in Fig 4 revealed that
TGF-b1 induced a 7.9-fold increase in a-smooth muscle actin
expression, and HMC-1 cell lysate induced a 2.7-fold increase. The
average induction in four separate experiments was 4.4-fold for
TGF-b1 and 2.1-fold for the HMC-1 lysate.
Initially we attempted to analyze cocultures of ®broblasts and
HMC-1 cells in the immunoblotting assay, and we did detect
increases in a-smooth muscle actin expression. The results
demonstrated wide ¯uctuations, which we believe were probably
caused by the variable but signi®cant numbers of HMC-1 cells that
attached to ®broblasts during coculture (Trautmann et al, 1997;
1998) and that could not be entirely removed by washing before
detergent solubilization of the ®broblast monolayer. In contrast,
HMC-1 cell lysate gave reproducible results in the immunoblotting
assay (Fig 4) and was also active in the collagen contraction assay.
The lysate induced 22%±36% of maximum contraction, which is
comparable to the contraction induced by intermediate numbers of
intact HMC-1 cells (Fig 3B). Heat inactivation of the lysate
completely eliminated its ability to induce a-smooth muscle actin
expression and to stimulate collagen contraction (data not shown).
Effects of histamine and TNF-a As HMC-1 cell lysate
appeared to be capable of inducing important features of the
myo®broblast phenotype, we examined the effects of several
speci®c mast cell products that might be responsible. A number of
potential mediators, including histamine (Nilsson et al, 1994;
Weber et al, 1996) and TNF-a (Grabbe et al, 1994; Nilsson et al,
1994), are produced by HMC-1 cells in vitro and by human mast
cells in vivo (Metcalfe et al, 1997). Figure 5 compares the effects of
TGF-b1, histamine, and TNF-a on the expression of a-smooth
muscle actin by human dermal ®broblasts. Although less potent
than TGF-b1, histamine also stimulated an increase in a-smooth
muscle actin expression. The average induction in three separate
experiments was 1.9-fold after treatment with 5 mg per ml
histamine. Unlike TGF-b1, however, histamine does not appear
to stimulate ®broblast contraction in the collagen contraction assay.
Incubation with 0.5±5 mg per ml histamine did not stimulate
®broblast contraction (data not shown). Incubation with H1 or H2
histamine receptor antagonists, to block the effects of histamine
released by HMC-1 cells, did not inhibit the contraction stimulated
by HMC-1 cells (data not shown). TNF-a had no signi®cant effect
on expression of a-smooth muscle actin (Fig 5) or on collagen
contraction (data not shown).
Effects of tryptase The serine protease tryptase is another mast
cell mediator produced by HMC-1 cells (Butter®eld et al, 1990;
Nilsson et al, 1994; Xia et al, 1995). We took several different
approaches to determine if tryptase can modulate the myo®broblast
phenotype. First, we used speci®c inhibitors of the enzymatic
activity of tryptase to determine if tryptase released by HMC-1 cells
contributes to the collagen contraction induced by HMC-1 cells.
When either BABIM (50 nM) or rLDTI (25 mM) was added to
collagen gels containing ®broblasts and HMC-1 cells, contraction
was only 0%±14% of maximum under conditions where
contraction in the absence of inhibitors was 50%±60% of
maximum. Neither tryptase inhibitor affected the contraction
response to PDGF-BB. Second, we tested puri®ed human lung
tryptase to determine if tryptase alone can induce a-smooth muscle
actin expression by human dermal ®broblasts. As shown in Fig 6, a
brief treatment with tryptase produced a clear increase in the
expression of a-smooth muscle actin by human dermal ®broblasts.
Furthermore, the induction produced by tryptase appeared to
require its enzymatic activity because that effect was blocked
substantially by pretreatment with AEBSF, an irreversible inhibitor
of serine proteases, but not by incubation with the combination of
soybean trypsin inhibitor and aprotinin, both of which inhibit most
Figure 2. HMC-1 cells induce a-smooth
muscle actin expression in dermal ®broblasts
in an organotypic model of skin. The
organotypic cultures were prepared and grown in
complete medium as described in Materials and
Methods. Shown on the left is a culture where
HMC-1 cells and dermal ®broblasts were
embedded in the collagen layer at a ratio of 1:4
(HMC-1 cells:®broblasts). Shown on the right is a
control culture with ®broblasts but no HMC-1
cells. The sections were stained ®rst for a-smooth
muscle actin and then counterstained with
hematoxylin. The arrows in the upper left panel
indicate ®broblasts stained positive for a-smooth
muscle actin. A dark band of strati®ed
keratinocytes, stained nonspeci®cally, is visible
above the layer of collagen containing ®broblasts
and HMC-1 cells. Upper scale bar: 30 mm; lower
scale bar: 15 mm.
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serine proteases except tryptase (Alter et al, 1990; Butter®eld et al,
1990; Schwartz, 1994).
DISCUSSION
Myo®broblasts play a central role in the normal process of wound
repair and in the dysregulated processes leading to ®brosis. As the
appearance of myo®broblasts often coincides with the presence of
mast cells, it seems quite likely that mediators produced by mast
cells are important for controlling the development and function of
myo®broblasts. We used the HMC-1 human mast cell line as an
experimental tool in an attempt to identify speci®c mast cell
products capable of inducing two particular features of the
myo®broblast phenotype. Histamine and tryptase, and the
HMC-1 cells, induced normal human dermal ®broblasts to express
a-smooth muscle actin, one distinguishing characteristic of differ-
entiated myo®broblasts. Tryptase and HMC-1 cells also stimulated
®broblast contraction of a collagen matrix, one important function
of myo®broblasts. Other myo®broblast functions, such as matrix
deposition (Gruber et al, 1997) and matrix remodeling (Gruber et al,
1989), may be subject to regulation by tryptase as well.
In some situations mast cells communicate with ®broblasts
through intimate physical contacts (Greenberg and Burnstock,
1983; Heard et al, 1992; Levi-Schaffer, 1995; Trautmann et al,
1997). One recent study (Yamamoto et al, 2000) concluded that
mast cells enhance ®broblast contraction of collagen lattices partly
by direct cell±cell interactions involving the c-kit receptor and the
c-kit ligand, also known as stem cell factor. The collagen gels used
in that study typically contained ®broblasts and HMC-1 cells at a
ratio of 1:5. Although we would expect those conditions to
promote more cell±cell interactions than the 1:1 ratio used in our
assay, we did observe that embedding HMC-1 cells in the collagen
gel stimulated contraction more effectively than simply adding any
single soluble mast cell product to the culture medium, which does
suggest that physical contact between the HMC-1 cells and the
®broblasts may contribute to the stimulatory signal. Close inter-
actions do not appear to be an indispensable part of the signaling
process, however. Soluble factors present in an HMC-1 cell lysate,
as well as puri®ed histamine and tryptase, had clear positive effects
on a-smooth muscle expression and collagen contraction. At least
some of the active factors in the cell lysate were sensitive to heat,
indicating that labile proteins such as tryptase might be involved.
Mast cells produce an array of pharmacologically potent
molecules affecting an astonishing number of biologic events,
including the differentiation and function of myo®broblasts.
Histamine (Nilsson et al, 1994; Weber et al, 1996), TNF-a
(Grabbe et al, 1994; Nilsson et al, 1994), and heparin (Nilsson et al,
1994) are produced by HMC-1 cells in vitro and by human mast
cells in vivo (Metcalfe et al, 1997). Histamine is a potent stimulus for
smooth muscle contraction, but in our collagen gel assay it did not
Figure 3. Collagen contraction assay. All of the collagen gels used in
these experiments contained a constant number of human dermal
®broblasts (250,000 cells per gel), and some of the gels also contained the
indicated number of HMC-1 cells. (A) Fetal bovine serum (10%),
PDGF-BB (5 ng per ml), and TGF-b1 (5 ng per ml) were added
separately to collagen gels containing only ®broblasts. Collagen gels
containing both ®broblasts and HMC-1 cells (250,000 cells per gel) did
not receive any additional stimulus. All gels were incubated for 72 h
before measurement. The results are expressed as a percentage of the
contraction stimulated by PDGF-BB, which was assigned the maximum
value of 100%. The data shown are means and SEM from seven
independent experiments with n = 16. Compared to control gels,
p = 0.00025 for all four stimuli. (B) Contraction was stimulated, as
described above, by PDGF-BB (5 ng per ml), TGF-b1 (5 ng per ml), or
a varying number of HMC-1 cells (from 10,000 to 250,000 cells per gel)
within the gel. Results are again expressed as a percentage of the
maximum contraction stimulated by PDGF-BB. The data shown are the
means and standard deviations from four independent experiments with
n = 10. (C) Kinetics of contraction stimulated by PDGF-BB (5 ng per
ml), TGF-b1 (5 ng per ml), or HMC-1 cells (250,000 cells per gel). The
amount of contraction was measured at 1 h intervals, and the results at
each time point are expressed as a percentage of the contraction
stimulated by PDGF-BB after 72 h.
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reproducibly stimulate ®broblast contraction. In one earlier study
using a similar assay, histamine did appear to stimulate ®broblast
contraction, although it was relatively weak compared to PDGF
(Clark et al, 1989). Consequently, it is still not clear whether or not
histamine plays a direct role in regulating myo®broblast function.
Nonetheless, we did observe that histamine could induce a-smooth
muscle actin expression (Fig 5), suggesting that histamine may play
a role in regulating myo®broblast differentiation. Histamine also
seems to be involved in modulating several other processes intrinsic
to wound repair and ®brosis, including ®broblast migration
(Kupietzky and Levi-Schaffer, 1996) and production of cytokines
(Zheng et al, 1994). TNF-a, in contrast to histamine, did not affect
either myo®broblast function or differentiation. We found no
indication that TNF-a by itself is a suf®cient stimulus for induction
of a-smooth muscle actin. It has been proposed, however, that
TNF-a can facilitate the mechanism through which heparin
stimulates expression of a-smooth muscle actin (DesmoulieÁre et al,
1992; Schmitt-GraÈff et al, 1994). Heparin and TNF-a are both
constituents of the granules of human tissue mast cells. TGF-b is
generally considered to be crucial for the regulation of myo®bro-
blast development and behavior in tissue (Powell et al, 1999; Serini
and Gabbiani, 1999), but we have been unable to demonstrate a
critical role for TGF-b in the HMC-1 cell coculture systems.
Our last set of experiments provided evidence of a surprising
new role for tryptase. Previous reports investigated the effects of
tryptase on ®broblast proliferation (Ruoss et al, 1991; Hartmann
et al, 1992; Abe et al, 1998) and collagen synthesis (Cairns and
Walls, 1997; Gruber et al, 1997; Abe et al, 1998), and more recent
studies focused on tryptase activation of PAR-1 and PAR-2
(Corvera et al, 1997; Mirza et al, 1997; Molino et al, 1997;
Schechter et al, 1998; Akers et al, 2000). We are not aware of any
studies published to date that speci®cally address tryptase regulation
of myo®broblast differentiation or function. Nonetheless, there
have been a number of relevant studies on thrombin stimulation of
®broblast contraction in a collagen matrix (Kolodney and
Wysolmerski, 1992; Kolodney and Elson, 1993; Pilcher et al,
1994; 1995), and there may be some common elements in
mechanisms through which tryptase and thrombin stimulate
contraction. One common feature, the requirement for enzymatic
activity, suggests that thrombin and tryptase may be signaling
through members of the family of protease-activated receptors
known as PARs (DeÂry et al, 1998). In fact, there is published
evidence that thrombin stimulates ®broblast contraction through
PAR-1 (Pilcher et al, 1994; 1995), and we have preliminary data
suggesting that tryptase may be signaling through PAR-2.
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